• 1
    Del Valle J, Chey WD, Scheiman JM. Chapter 66: Acid-peptic disorders. In: Yamada, T, ed. Textbook of Gastroenterology, 4th edn. Philadelphia, PA: JM Lippincott, 2003: 132176.
  • 2
    IMS Health. National Prescription Audit PlusTM, 2004 (January 2004-December 2004).
  • 3
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 188899.
  • 4
    Peloso PM, Scheiman JM. The economic implications of COX-2 specific inhibitors. Am J Med 2001; 110: 50S4S.
  • 5
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 6
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 124755.
  • 7
    Goldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20: 52738.
  • 8
    Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested cast-control analysis. Br Med J 2005; 330: 13669.
  • 9
    Lévesque LE, Brophy JM, Zhang B. The risk of myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 4819.
  • 10
    Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2002; 162: 16975.
  • 11
    Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 103843.
  • 12
    U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 15760.
  • 13
    Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 52732.
  • 14
    Singh G, Ramey DR, Morfield D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 15306.
  • 15
    Scheiman JM, Fendrick AM. NSAIDs without a prescription: over-counter access, under counted risks. Am J Gastroenterol 2002; 97: 215960.
    Direct Link:
  • 16
    Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 2002; 136: 16172.
  • 17
    Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 82730.
  • 18
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 2000; 321: 11837.
  • 19
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 203388.
  • 20
    Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 14136.
  • 21
    Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395402.
  • 22
    Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Coxibs, NSAIDs, Aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology 2005; 128: A-94 (abstract 629).
  • 23
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 1422.
  • 24
    Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97: 220814.
    Direct Link:
  • 25
    Hawkey CJ, Næsdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51: 33643.
  • 26
    Chan FKL, To KF, Wu JCY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002; 359: 913.
  • 27
    Lai KC, Lam SK, Chu CM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trial. Aliment Pharmacol Ther 2003; 18: 82936.
  • 28
    Saad R, Chey WD. A clinician's guide to the diagnosis and treatment of H. pylori. Clev Clin J Med 2005; 72: 10926.
  • 29
    Fendrick AM, Bandekar RR, Chernew ME, et al. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Care Res 2002; 47: 3643.
  • 30
    Spiegel BMR, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795806.
  • 31
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 9549.
  • 32
    Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004; 20: 32131.
  • 33
    American Medical Association. Physicians in the United States and Possessions by Selected Characteristics. Chicago: c. 19952004 [updated 2004 Jun 24; cited 2004 Nov. 12]. Available at: